Lisa Parrillo, MD
Urology · Meridian, IDNPI 1659663482
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,891 of the $3,443 with a category attached, or 84.0%. Medtronic accounts for 64.9% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $1,222, 3.0 times the $407 reported in 2019.
Across 79 payments — averaging $43.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- AbbVie$415
- Astellas Pharma US Inc$138
- Merck$135
- Baxter Healthcare$101
- Urogen Pharma, Inc.$85
- plus $336 from 12 others
Across 1 payment — averaging $12,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Uromedica, Incorporated$12K
What the payments were for
- Travel & lodging$54516%
- Food & beverage$2,89184%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 28 | $2,234 |
| AbbVie(2 entities) | 17 | $415 |
| Astellas Pharma US Inc | 6 | $138 |
| Merck | 5 | $135 |
| Baxter Healthcare | 1 | $101 |
| Urogen Pharma, Inc. | 5 | $85 |
| Laborie Medical Technologies Corp. | 1 | $74 |
| Olympus America Inc. | 3 | $47 |
| Bluewind Medical | 1 | $39 |
| Dendreon Pharmaceuticals LLC | 2 | $37 |
| AstraZeneca | 2 | $30 |
| Johnson & Johnson | 1 | $21 |
| Neotract Inc. | 1 | $20 |
| Myovant Sciences Inc. | 1 | $16 |
| Vertex | 1 | $16 |
| Boston Scientific | 1 | $14 |
| Endo USA, Inc. | 1 | $14 |
| Travere Therapeutics, Inc. | 2 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,443 in reported general payments places this provider in the 55th percentile of 55 urology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 284 | $214,447 |
| GemtesaVibegron | 36 | $21,835 |
| Estradiol | 289 | $12,472 |
| Solifenacin Succinate | 88 | $9,521 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 70 | $8,976 |
| Methenamine Hippurate | 69 | $4,414 |
| Finasteride | 234 | $2,923 |
| Potassium Citrate ErPotassium Citrate | 20 | $2,913 |
| Tolterodine Tartrate ErTolterodine Tartrate | 15 | $2,630 |
| Tamsulosin Hcl | 233 | $2,290 |
| Cephalexin | 84 | $1,129 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 52 | $788 |
| Trimethoprim | 13 | $705 |
| Oxybutynin Chloride ErOxybutynin Chloride | 36 | $371 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 28 | $300 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $138 | $214,447284 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 55 urology providers in Idaho.
Other urology in Meridian
- Wade MunceyMeridian$9K
- John GreerMeridian$8K
- Dawn KingMeridian$8K
- Helen KuoMeridian$5K
- Brian AugeMeridian$5K
- Michael JacobsonMeridian$4K
- Kara SaperstonMeridian$4K
- Joseph WilliamsMeridian$4K
- Michael TaylorMeridian$3K
- Jared HeinerMeridian$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.